Study on Antibodies against Salvinorin A and Wogonin Glucuronide for Immunoassays by マダン クマル　ポウデル
（製本の際の表紙見本）          
 
 
博士論文 
 
 
 
サルビノリンＡとオウゴニングルクロニドに対する
抗体の作製ならびにイムノアッセイに関する研究  
 
 
 
 
 
 
 
 
 
平成２8 年度 
ポウデル マダン クマル 
 Study on Antibodies against Salvinorin A and 
Wogonin Glucuronide for Immunoassays 
 
 
 
 
Paudel Madan Kumar 
 
 
 
 
A dissertation submitted in partial fulfillment of the requirements 
for the degree of Doctor of Philosophy 
 
 
 
 
 
Department of Pharmacognosy 
Graduate School of Pharmaceutical Sciences  
 Showa Pharmaceutical University, 2017 
 
 
 
 
 
 
 
 
TABLE OF CONTENTS 
 
PAGE 
LIST OF ABBREVIATIONS         i 
LIST OF PUBLICATIONS         iv 
LIST OF TABLES         v 
LIST OF FIGURES         vi 
 
CHAPTER 
 
1. General introduction        1 
 
2. Production of monoclonal antibody against  salvinorin A and its application in 
Enzyme-Linked Immunosorbent Assay      2 
 
I. Introduction        2  
II. Materials and Methods      4 
III. Results and Discussion      11  
IV. Conclusion        18 
 
3. Development of a combined technique using a one -step immunochromatographic assay 
and ELISA for the rapid detection of Sal A      19 
 
I. Introduction        19 
II. Materials and Methods      20  
III. Results and Discussion      22  
IV. Conclusion        26  
 
4. Production of monoclonal antibody against  wogonin glucuronide and its application 
in ELISA          27 
 
I. Introduction        27  
II. Materials and Methods      29  
III. Results and Discussion      36  
IV. Conclusion        42  
 5. Study of different peptide linker lengths of single chain variable fragment against 
wogonin glucuronide        43 
I. Introduction        43  
II. Materials and Methods      45  
III. Results and Discussion      50  
IV. Conclusion        56  
 
 
6. An overview and comparison of two recombinant antigen-binding fragment and 
antigen-binding fragment from monoclonal antibody against wogonin glucuronide   
 
I. Introduction        57  
II. Materials and Methods      58  
III. Results and Discussion      61  
IV. Conclusion        68  
 
 
7. Conclusion         69 
 
 
REFERENCES          71  
 
ACKNOWLEDGEMENTS        86  
 
i 
 
LIST OF ABBREVIATIONS  
 
A B T S  
2 ,  2 ' - a z i n o - b i s  ( 3 - e t h yl b e n z o - t h i az o l i n e - 6 - s u l f o n i c  a c i d )  
d i am m o n i u m  
b p  b a s e p a i r  
B S A  b o v i n e  s e r u m  a l b u m i n  
c D N A  c o m p l em e n t a r y  d e o x yr i b o n u c l e i c  a c i d  
C D R s  c o m p l em e n t a r i t y  d e t e r m i n i n g  r e g i o n s   
C R s  c r o s s - r e a c t i v i t i e s  
D N A  d eo x yr i b o n u c l e i c  a c i d  
D M A P  4 - d i m e t h yl a m i n o p yr i d i n e  
E D C  1 - e t h yl - 3 - ( 3 ’ - d i m e t h yl a m i n o p r o p yl )  c a r b o d i i m i d e  H C l  
E D T A  e t h yl e n e d i am i n e  t e t r a a c e t i c  a c i d  
E L I S A  e n z ym e - l i n k ed  i m m u n o s o r b e n t  a s s a y  
eR D F  e n r i c h - R P M I 1 6 4 0 - D u l b e c c o ` s - H a m ` s  F 1 2  M ed i u m  
E R  e n d o p l a s m i c  r e t i cu l u m  
F a b  a n t i g e n  b i n d i n g  f r a g m e n t  
F C S  f e t a l  c a l f  s e r u m  
F i g  f i g u r e  
F v  v a r i a b l e  f r a g m e n t  
G C  g a s  ch r o m a t o g r a p h y  
H A T  h yp o x a n t h i n e - am i n o p t e r i n - t h ym i d i n e  
H P LC  h i g h - p e r f o r m an c e  l i q u i d  c h r o m a t o g r a p h y  
H R P  h o r s e r ad i s h  p e r o x i d a s e  
H S A  h u m an  s e r u m  a l b u m i n  
H V J  h em a g g l u t i n a t i n g  v i r u s  o f  J ap a n  
IC A  i m m u n o c h r o m a t o g r a p h i c  a s s a y   
IC  i m m u n o c h r o m a t o g r a p h i c  
ii 
 
i c E L IS A  i n d i r e c t  c o m p e t i t i v e  E L IS A  
IP T G  i s o p r o p yl - D - t h i o g a l a c t o p yr a n o s i d e  
I g G  i m m u n o g l o b u l i n  G  
K D  d i s s o c i a t i o n  co n s t a n t  
k D a  k i l o d a l t o n  
LC  l i q u i d  ch r o m a t o g r a p h y  
M A b  m o n o c l o n a l  a n t i b o d y  
M A LD I  m a t r i x - a s s i s t e d  l a s e r  d e s o r p t i o n / i o n i z a t i o n .  
M S  m a s s  s p e c t r o m e t r y  
m R N A  m e s s e n g e r  r i b o n u c l e i c  a c i d  
M S  
m e d i u m  
M u r a s h i g e - S k o o g  m e d i u m  
N M R  n u c l e a r  m a g n e t i c  r e s o n an c e  
O D  o p t i c a l  d en s i t y  
O V A  o v a l b u m i n  
P A b  p o l yc l o n a l  a n t i b o d y  
P BS  p h o s p h a t e - b u f f e r e d  s a l i n e  
P BS - s m  P BS  c o n t a i n i n g  5 %  s k i m  m i l k  
P BS - T  P BS  c o n t a i n i n g  0 . 0 5 %  t w e e n  2 0  
P C R  p o l ym e r a s e  ch a i n  r e a c t i o n  
P E G  p o l ye t h yl e n e  g l yc o l  
r p m  r e v o l u t i o n s  p e r  m i n u t e  
S a l  A  s a l v i n o r i n  A  
S a l  B  s a l v i n o r i n  B  
s c Fv  s i n g l e  c h a i n  v a r i a b l e  f r a g m e n t  
S D S - PA G E  s o d i u m  d o d e c yl  s u l f a t e  p o l ya c r y l a m i d e  g e l  e l e c t r o p h o r e s i s  
S D W  s t e r i l e  d i s t i l l ed  w a t e r  
S O E - P C R  s p l i c i n g  b y  o v e r l a p p i n g  ex t en s i o n  p o l ym e r a s e  ch a i n  
iii 
 
r e a c t i o n  
S P BS  P BS  c o n t a i n i n g  5 %  s k i m  m i l k  
T A E  
b u f f e r  
t r i s - a c e t a t e - E D T A  b u f f e r  
T E  t r i s - E D T A  
T F A  t r i f l u o r o a c e t i c  a c i d  
T LC  t h i n  l a ye r  c h r o m a t o g r a p h y  
T P B S  P BS  c o n t a i n i n g  0 . 0 5 %  T w e en - 2 0  
T O F  t i m e  o f  f l i g h t  
T S P   t o t a l  s o l u b l e  p r o t e i n  
T w e en  2 0  p o l yo x ye t h yl e n e  ( 2 0 )  s o r b i t an  m o n o l a u r a t e  
U V  u l t r a  v i o l e t  
V H  h e av y  c h a i n  v a r i ab l e  r e g i o n  
V H - C H 1  h e av y  c h a i n  v a r i ab l e  r e g i o n  w i t h  co n s t a n t  r e g i o n   
V L  l i g h t  c h a i n  v a r i a b l e  r e g i o n  
V L- C L  l i g h t  c h a i n  v a r i a b l e  r e g i o n  w i t h  c o n s t a n t  r e g i o n  
W gn  w o g o n i n - 7 - O - - D - g l u cu r o n i d e  
X - g a l  5 - b r o m o - 4 - c h l o r o - 3 - i n d o yl -D - g a l a c t o p yr a n o s i d e  
  
  
 
 
 
 
 
 
 
iv 
 
LIST OF PUBLICATIONS  
 
T h i s  d i s s e r t a t i o n  i s  a  s u m m a r y  o f  g r a y  n u m b er e d  m a n u s c r i p t s  a s  f o l l o w s ;  
 
1 .  P a u d e l  M . K . ;  P u t a l u n  W. ;  S r i t u l a r a k  B. ;  M o r i n a g a  O . ;  S h o ya m a  Y. ;  
Tan a k a  H . ;  M o r i m o t o  S .  D e v e l o p m en t  o f  a  c o m b i n e d  t e c h n i q u e  u s i n g  a  
o n e - s t e p  i m m u n o c h r o m a t o g r a p h i c  a s s a y  a n d  i n d i r e c t  c o m p e t i t i v e  E L I S A 
f o r  t h e  r a p i d  d e t e c t i o n  o f  b a i c a l i n  A n a l .  C h i m .  A c t a  2 0 11 ,  7 0 1 ,  1 9 0 - 1 9 4 .  
 
2 .  P a u d e l ,  M. K . ;  Ta k e i  A . ;  S a k o d a  J . ;  J u en g w a t a n a t a k u l  T. ;  S a s a k i - Ta b a t a  
K . ;  Tan a k a  H . ;  M o r i m o t o  S .  P r e p a r a t i o n  o f  a  s i n g l e - c h a i n  v a r i ab l e  
f r a g m e n t  a n d  a  r e c o m b i n an t  a n t i g e n - b i n d i n g  f r a g m e n t  a g a i n s t  
a n t i - m a l a r i a l  d r u g s ,  a r t e s u n a t e  an d  a r t e m i s i n i n , a n d  t h e  a p p l i c a t i o n  f o r  
E L I S A  A n a l .  C h em .  2 0 1 2 ,  8 4 ,  2 0 0 2 - 2 0 0 8 .  
 
3 .  C h a o  Z . ;  T a n  M . ;  P a u d e l  M. K . ;  S a k a m o t o  S . ;  M a  L . ;  S a s ak i - T a b a t a  K . ;  
T an a k a  H . ;  S h o ya m a  Y . ;  X u a n  L . ;  M o r i m o t o  S .  D e v e l o p m e n t  o f  a n  
i n d i r e c t  c o m p e t i t i v e  en z ym e - l i n k e d  i m m u n o s o r b e n t  a s s a y  ( i c E L IS A )  
u s i n g  h i g h l y  s p e c i f i c  m o n o c l o n a l  a n t i b o d y  a g a i n s t  p a c l i t ax e l  J  N a t .  M e d .  
2 0 1 2  6 7 ( 3 ) ,  5 1 2 - 5 1 8 .  
 
4 .  P a u d e l  M . K . ,  S h i r o t a  O . ;  S a s a k i - Ta b a t a  K . ;  Tan a k a  H . ;  S e k i t a  S . ;  
M o r i m o t o  S .  D e v e l o p m en t  o f  a n  en z ym e  i m m u n o a s s a y  u s i n g  a  
m o n o c l o n a l  a n t i b o d y a g a i n s t  t h e  p s yc h o a c t i v e  d i t e r p e n o i d  s a l v i n o r i n  A 
J .  N a t .  P r o d .  2 0 1 3 ,  7 6 ( 9 ) ,  1 6 5 4 - 1 6 6 0 .  
 
5 .  S a k am o t o  S . ;  Yu s a k u l  G . ;  P o n g k i t w i t o o n  B . ;  P a u d e l  M . K . ;  Tan a k a  H . ;  
M o r i m o t o  S .  S i m u l t a n e o u s  d e t e r m i n a t i o n  o f  s o y  i s o f l a v o n e  g l yc o s i d e s ,  
d a i d z i n  a n d  g e n i s t i n  b y  m o n o c l o n a l  an t i b o d y - b a s ed  h i g h l y  s e n s i t i v e  
i n d i r e c t  c o m p e t i t i v e  en z ym e - l i n k e d  i m m u n o s o r b en t  a s s a y  F o o d  C h em .  
2 0 1 5 ,  1 6 9 ,  1 2 7 - 1 3 3 .  
 
6 .  P a u d e l  M. K . ;  S ak a m o t o  S . ;  H u y L . V. ;  Tan a k a  H . ;  M i ya m o t o  T. ; Tak a n o  
A . ;  M o r i m o t o  S .  D e v e l o p m en t  o f  a n  i m m u n o as s a y  u s i n g  a n  a n t i - w o g o n i n  
g l u cu r o n i d e  m o n o c l o n a l  an t i b o d y  J . I m m u n o as s a y  Im m u n o c h em i s t r y,  
2 0 1 7 .  
v 
 
LIST OF TABLES 
 
 
TA B L E  PA G E  
1  I n t e r  an d  i n t r a  a s s a y  p r e c i s i o n  o f  S a l  A b y  t h e  i c E L I S A 
u s i n g  M A b  3 D 5  
1 7  
2  R e c o v e r y  o f  S a l  A f r o m  s p i k e d  s am p l e s  u s i n g  t h e  
i c E L IS A .  
1 8  
3  D e t e r m i n a t i o n  o f  s a l v i n o r i n s  b y  u s i n g  i c E L IS A a n d  
v i s u a l  i n d i c a t i o n  o f  IC A  
2 6  
4  C R s  o f  M A b  3 1 5 A  a g a i n s t  W g n  a n d  s t r u c t u r a l l y  r e l a t e d  
c o m p o u n d s  
3 9  
5  I n t e r  an d  i n t r a  a s s a y  p r e c i s i o n  o f  t h e  an a l y t i c a l  m e t h o d  
f o r  W g n  u s i n g  t h e  i c E L IS A  
4 0  
6  R e c o v e r y  o f  W g n  f r o m  s p i k ed  s am p l e s  u s i n g  t h e  
i c E L IS A  
4 1  
7  D e t e r m i n a t i o n  o f  W gn  i n  S .  R a d i x e s  b y  t h e  i c E L I S A 
u s i n g  M A b  3 1 5 A  
4 2  
8  P r i m e r s  u s e d  t o  c o n s t r u c t  t h e  W g n - s c F v  g e n e s  4 7  
9  C R s  o f  W g n - s c F v  a g a i n s t  W g n  a n d  s t r u c t u r a l l y  r e l a t e d  
c o m p o u n d s  
5 4  
1 0  I n t e r  an d  i n t r a  a s s a y  p r e c i s i o n  o f  t h e  i c E L I S A u s i n g  
W gn - s c F v  
5 5  
11  D e t e r m i n a t i o n  o f  W gn  i n  S .  R a d i x e s  b y  t h e  i c E L I S A 
u s i n g  a n t i - W g n - s c F v  
5 6  
1 2  P r i m e r s  u s e d  t o  c o n s t r u c t  t h e  W g n - F a b  g e n e s  5 9  
1 3  C R s  o f  F a b s  a g a i n s t  W g n  a n d  s t r u c t u r a l l y  r e l a t ed  
c o m p o u n d s  
6 6  
1 4  I n t e r  an d  i n t r a  a s s a y  p r e c i s i o n  o f  t h e  i c E L I S A f o r  
a n t i - W g n  F a b    
6 7  
1 5  D e t e r m i n a t i o n  o f  W gn  i n  S .  R a d i x e s  b y  t h e  i c E L I S A 
u s i n g  a n t i - W g n  F a b  
6 8  
 
 
 
vi 
 
LIST OF FIGURES 
 
 
F I G U R E  PA G E  
1 .  S t r u c t u r e  o f  s a l v i n o r i n  A an d  s a l v i n o r i n  B  3  
2 .  S yn t h e s i s  o f  S a l  B - c o n j u g a t e s  5  
3 .  P r o t o co l  o f  i n d i r e c t  E L I S A  8  
4  P r o t o co l  o f  i n d i r e c t  c o m p e t i t i v e  E L IS A  1 0  
5 .  D i r e c t  d e t e r m i n a t i o n  o f  h a p t e n  n u m b e r  o f  S a l  B - B S A 
c o n j u g a t e s  b y  M A L D I- TO F - M S  
1 3  
6 .  S t an d a r d  c u r v e s  f o r  S a l  A i n  i c E L IS A u s i n g  M A b  3 D 5  1 4  
7 .  C R s  o f  M A b  3 D 5  a g a i n s t  S a l  A an d  s t r u c t u r e  r e l a t ed  
c o m p o u n d s  
1 6  
8 .  ( a )  T h e  s t r i p  t e s t  i s  b a s e d  o n  a  co m p e t i t i v e  
i m m u n o a s s a y  m e t h o d o l o g y  u s i n g  a n t i - S a l  A M A b  a s  t h e  
d e t e c t i o n  r e a g e n t .  ( b )  c o l o r  o n l y  a p p e a r s  i n  t h e  C . z o n e  
i f  a  s am p l e  i s  p o s i t i v e . f o r  s a l v i n o r i n  ( c )  co l o r  ap p e a r s  
i n  b o t h  T a n d  C  z o n e  i f  s am p l e  i s  f r e e  o f  S a l  A  
2 0  
9 .  V i s u a l  i n d i c a t i o n s  o b t a i n e d  u s i n g  
i m m u n o c h r o m a t o g r a p h i c  s t r i p  t e s t  f o r  S a l  A  s h o w i n g  
( A )  A  n e g a t i v e  s a m p l e ,  ( B )  a  p o s i t i v e  s a m p l e  
2 3  
1 0 .  D e t e r m i n a t i o n  o f  t h e  d e t e c t i o n  l i m i t  f o r  t h e  IC A o f  S a l  
A  
2 4  
11 .  V i s u a l  i n d i c a t i o n s  o b t a i n e d  u s i n g  
i m m u n o c h r o m a t o g r a p h i c  s t r i p  t e s t  f o r  S a l  A  s h o w i n g  
L a n e ’ s  1 - 5  S .  d i v i n o r u m  an d  l an e  6 - 1 0  S a l v i a  s p p .  ( S .  
f a r i n a c e a ,  S  . p a t e n s ,  S  . m i c ro p h y l l a ,  O c i m u m  
b a s i l i c u m ,  a n d  R o s m a r i n u s  o f f i c i n a l i s )   
2 5  
1 2 .  S cu t e l l a r i a  b a i c a l e n s i s   2 7  
1 3 .  C h em i c a l  s t r u c t u r e s  o f  m a j o r  b i o a c t i v e  f l a v o n e s  i n  S .  
R a d i x  
2 8  
1 4 .  S yn t h e s i s  o f  W g n - C a r r i e r  p r o t e i n  c o n j u g a t e s  3 2  
1 5 .  D i r e c t  d e t e r m i n a t i o n  o f  t h e  h a p t e n  n u m b e r  o f  W g n - B S A 
c o n j u g a t e s  b y  M A L D I - TO F - M S  
3 7  
1 6 .  S t an d a r d  c u r v e  f o r  W g n  b a s ed  o n  i c E L IS A  u s i n g  3 1 5 A  3 8  
1 7 .  S t r u c t u r e  o f  I g G  a n t i b o d y  a n d  s c F v  a n t i b o d y  4 5  
1 8 .  N u c l e o t i d e  an d  d e d u c ed  am i n o  a c i d  s e q u e n c e  o f  5 1  
vii 
 
W gn - s c F v  
1 9 .  S D S - PA G E  a n a l ys i s  o f  a n t i - W g n - s c F v s  3 L ,  5 L a n d  7 L 
ex p r e s s e d  i n  E . co l i  B L2 1  ( D E 3 )  
5 2  
2 0 .  S t an d a r d  c u r v e  f o r  W g n  b a s e d  o n  i c E L IS A u s i n g  
W gn - s c F v  
5 3  
2 1 .  S t r u c t u r e  o f  I g G  a n t i b o d y  a n d  F a b  a n t i b o d y  5 8  
2 2 .  N u c l e o t i d e  an d  d e d u c ed  am i n o  a c i d  s e q u e n c e  o f  
V H - C H 1  a n d  V L - C L  
6 2  
2 3 .  S D S - PA G E  a n a l ys i s  o f  V H - C H 1  a n d  V L - C L ex p r e s s ed  
i n  E . c o l i  B L2 1 ( D E 3 )  
6 3  
2 4  N a t i v e  S D S  p a g e  M :  m a r k e r ;  1 :  R e f o l d e d  V L- C L;  2 :  
R e f o l d e d  V H - C H 1 ;  3 :  R e f o l d e d  F a b  
6 4  
2 5  S t an d a r d  c u r v e  o f  W gn  u s i n g  W g - F a b  ( r e f o l d e d )  i n  t h e  
i c E L IS A  
6 5  
 
 1 
 
CHAPTER 1 
 
General Introduction 
 
The richness and diversity of plants are fascinating. People have harnessed the 
usefulness of plants for various purposes – agronomy, jewelry and even medicines. In 
particular, medicinal plants hold the highest value and are traded at a good price.  
However, with the recent increase of consumption of medicinal plants and resource 
depletion by indiscriminate picking of wild plants, medicinal plant resources have 
decreased. Therefore, the cultivation and breeding of the useful medicinal plants are 
carried out actively. Various aims are considered to generate medicinal plants with high 
added value. Among them, there is a direction to obtain individuals containing active 
substances in high concentration. In such a study, a method which is capable of 
simultaneously analyzing a large number of samples becomes a convincing tool. 
Immunoassay is such a method that has ideal  characteristics as an above-mentioned 
analytical method for a breeding study. Our group has studied preparation of 
monoclonal antibodies (MAbs) against secondary metabolites and developed 
immunoassays for generation of medicinal plants containing them in high concentration. 
The methods using MAbs are also useful for identification and a quality control of 
products made from medicinal plants.  
In the dissertation, two kinds of Lamiaceae plants, Salvia and Scutellaria, have been 
studied in terms of preparation of MAbs and recombinant antibodies to active secondary 
metabolites in each medicinal plant and establishment of convenient immunoassays.  
 2 
 
CHAPTER 2 
 
Production of Monoclonal Antibody against Salvinorin A and Its 
Application in Enzyme-Linked Immunosorbent Assay 
 
1. INTRODUCTION 
Salvia divinorum  (S. divinorum) originally from Mexico belongs to the Lamiaceae 
(Labiate, or Mint) Family. It is well recognized for its psychoactive properties. It is a 
perennial plant having blue or white flowers. This plant is used by southern Mexic an 
people as a traditional medicine. Although it is a hallucinatory plant whereas it has 
various pharmacological activities.  S. divinorum is a promising resource for drug 
development with its medicine applications.  
 Salvinorin A (Sal A, Fig. 1) is the main psychoactive compound in S. divinorum , 
which is a potent -opioid agonist. Its structure is a neoclerodane diterpene (Ortega, 
A.; 1982, Siebert, D.J.; 1994, Roth, B.L.; 2002 and Sheffler, D.J.; 2003). It is used as 
a traditional remedy for the treatment of diarrhea, pain, headache , rheumatism and 
inflammatory disorders and migraine  (Vortherms, T.A.; 2006). Sal A shows low toxicity 
as well as low addictive potential  (Scheerer, J.R.; 2007, Yang, L.; 2009, Hagiwara, H.; 
2009, Yan, F.; 2009, Lee, D.Y.M.; 2009, Lozama, A.; 2011 and Finc hna, J.; 2011). 
Currently, it is one of the popular element of drug development.  
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Fig. 1: Structure of salvinorin A (R= OAc) and salvinorin B (R= OH) 
 
 Meanwhile, 200-500g Sal A in humans induces profound hallucinations 
lasting up to 1 h, which may loss of awareness, identity, and control of body (Chartoff, 
E.H.; 2008, Braida, D.; 2009 and McCurdy, C.R.; 2006) . Interestingly, there are several 
studies suggested on the inclusion of endocannabinoid system mediation as some of its 
effects as of later effect (Capasso, R.; 2008). 
 As to analyses of Sal A, a lot of analytical approaches such as thin layer 
chromatography (TLC) and gas chromatography mass spectrometry (GC/MS) have been 
reported (Pichini, S; 2005, Kennedy, J.H.; 2010 and Jermain, J.D.; 2009) . It is also 
reported that high performance liquid chromatography (HPLC) with tandem mass 
spectrometry (LC/MS) are used as a quantitative analysis not just for plant materials, 
but also for biological samples from consumers  (Schimidt, M.S.; 2005 and Tsujikawa, 
K.; 2008).    
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2. MATERIALS AND METHODS 
2.1.  Materials 
 Sal A and related compounds, i.e. Sal B, C, D, E, and F; divinnatorins A and B; 
Salvidivins A, B, C, and D, C8-epi Salvinorin B, C8-epi-salvinorin were obtained by 
Prof. Osamu Shirota, Tokushima Bunri University. Bovine serum albumin (BSA) and 
Human serum albumin (HSA) were obtained from Sigma (Steinheim, Germany). 
Freund`s complete and incomplete adjuvants were purchased from Difco (Detroit, USA). 
POD-anti mouse IgG (Whole molecule) were obtained from MP Biomedical (Solon, OH, 
USA). All other chemicals and organic solvents were standard commercial products of 
analytical-reagent grade. 
  
2.2.  Sample preparations 
 The 30 mg leaf samples of S. divinorum and other Lamiaceae plants (Chapter 2 
and 3); were weighted and grinded to fine powder. Each sample was extracted with 0.5 
mL methanol using ultrasonic bath for 10 minutes. The extract was then centrifuged at 
12,000 rpm for 15 min, and the supernatant was moved into a glass test tube. This 
extraction step was repeated three times and each one of the supernatant was mixed to 
set up a sample solution. The extracted solution was evaporated until dry. The extract 
was determined in methanol (1 mL) and diluted properly for ELISA and ICA examine.  
 
2.3.  Synthesis of Sal B conjugate 
 The Sal B hemi succinate was a hapten and conjugated to BSA and HSA as an 
immunogen and coating antigen, individually. Sal B hemi succinate (5.0 mg, 0.023 
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mmol) and 1-Ethyl-3-(3`-dimethylaminopropyl)-carbodiimide hydrochloride (EDC, 6.0 
mg, 0.031 mmol) were added to a solution mixture of 30% pyridine (0.5 mL). The 
reaction mixture was added drop by drop with H2O (0.25 mL) containing BSA (5.0 mg) 
or HSA (5.0 mg), and then mixed at room temperature for 7 h. The mixture was dialyzed 
with 5 changes of H2O at 4℃ for 3 days, and lyophilized to give 6.20 mg Sal B-BSA 
conjugate and 8.40 mg Sal B-HSA conjugate, respectively (Chapter 2 and 3).  
 
Fig. 2: Synthesis of Sal B-conjugate 
 
2.4.  Determination of hapten number in Sal B conjugates by MALDI -TOF-MS  
 The hapten numbers of Sal B-BSA and Sal B-HSA conjugates were dictated by 
MALDI-TOF-MS. A little sum (1-10 pmol) of an antigen conjugate was mixed with a 
103-fold molar abundance of sinapinic acid in an aqueous mixture which contain 0.10% 
tri-fluroacetic acid. The mixture solution was subjected to an elite MALDI -TOF-MS 
system, Autoflex III (Brucker Daltonics, Bremen, Germany). The  data and information 
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were analyzed utilizing flex analysis 3.0.92.  
2.5.  Immunization, hybridization, and production of MAb  
 5 weeks old male BALB/c mice were obtained from KBT Oriental Co., Saga, 
Japan. Diet (MF; Oriental Yeast Co., Tokyo, Japan) and water w as given ad libitum . 
Animal consideration and all methods were endorsed by the Committee of Ethics of 
Animal Experiments, Graduate School of Pharmaceutical Sciences, Kyushu University, 
and were led by Guidelines for Animal Experiments of the Graduate Schoo l of 
Pharmaceutical Sciences, Kyushu University (Approval A-26-013-0). 
 To set up an immunogen solution, Sal B-BSA conjugates were dissolved in 8 M 
urea and diluted with PBS. Mouse was injected intraperitoneally with 0.5 mL of immune 
solution (100 g/mL emulsified with an equivalent volume of Freund`s complete 
adjuvant). The second immunization, (50 g/mL of the conjugate in Freund`s 
incomplete adjuvant) was regulated into stomach cavity of mouse intraperitoneally two 
weeks after the initial injection. The mouse was also given supplements of immunogen 
(100 g) without an adjuvant into stomach cavity at the third and last immunization. 
Mouse bled on the fourth day after every help and titer of particular antibodies 
perceiving Sal A in the sera were observed by ELISA. Splenocytes were set up from a 
detached spleen and fused with a HAT sensitive mouse myeloma cell line, SP2/0 -Ag14, 
utilizing the HVJ envelop method (Ishihara Sangyo Kaisha Ltd., Osaka, Japan).  
 Hybridomas creating MAb reactive to Sal A were  cloned utilizing the 
constrained dilution technique (Goding, 1980). Chosen hybridoma clones were refined 
in an enhanced RPMI 1640-Dulbecco`s-Ham`s F12 (e-RDF) medium (Kyokuto 
Pharmaceutical Industrial Co. Ltd., Tokyo, Japan) supplemented with 10% fetal bo vine 
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serum (FBS), for the most part. On account of planning of MAb, a serum free medium, 
an e-RDF medium supplemented with 10 g/mL insulin, 35 g/mL transferrin, 20 g/mL 
ethanolamine and 25 nM selenium, was utilized to get a supernatant containing MAb 
3D5. 
 
2.6.  Purification of MAb 
 MAb secreted from hybridoma was refined utilizing a Protein G FF column (0.46 
cm x 11 cm, GE Health Care, Uppsala, Sweden). The cultured medium (500 mL) 
containing IgG was changed in accordance with pH 7.0 with 1 M Tris -HCl solution pH 
9.0 and applied to the column, and the column was washed with 10 mM phosphate buffer, 
pH 7.0. Adsorbed IgG was eluted with 100 mM citrate buffer, pH 3.0. The eluted IgG 
was neutralized with 1 M Tris-HCl (pH 9.0), dialyzed three times against H 2O, and 
lyophilized to give 8.3 mg MAb 3D5.  
 
2.7.  Indirect ELISA using coating antigen   
 The reactivity of the MAb to coating antigen was dictated by indirect ELISA. 
The 96-wells immunoplate (Maxisorb, Nalgene Nunc, and Roskilde, Denmark) was 
coated with 100 L of antigen in carbonate buffer (50 mM, pH 9.6) and incubated at 
37 ℃  for 1h. The concentration of coating antigen Sal B-HSA is 0.1 g/mL. The plate 
was washed three times with 0.05% Tween 20 containing PBS (PBST).  It was then 
treated with 300 L of PBS containing 5% skim milk (SPBS) for 1h to decrease non-
particular adsorption. At that point, the plate was washed three times with PBST and 
responded with 100 L of testing antibodies for 1h. The plate was washed again with 
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PBST three times. The MAbs was then joined with 100 L of 1000-fold diluted solution 
of POD-labelled anti-mouse IgG (Biomedical, Cappel Products, CA) for 1h. In the wake 
of washing the plate three times with PBST, 100 L of substrate solution, 0.1 M citrate 
buffer (pH 4.0) containing 0.003% H2O2 and 0.3 mg/mL 2, 2`-azino-bis (3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) (Wako, Osaka, Japan) 
were added to every well and incubated for 15 min. Absorbance at 405 nm was measured 
by a microplate reader (ImmunoMini, Nunc). All r eactions were completed at 37 ℃ .  
The Fig. 3 shows the indirect ELISA procedures which is followed in the whole 
dissertation.  
  
 
Fig. 3: Protocol of indirect  ELISA 
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2.8.  icELISA using anti-Sal A and Wgn MAbs 
 The procedures for the icELISA were followed by the coating antigen (100 L)  
dissolved in  50 mM carbonate buffer (pH 9.6) was adsorbed to the 96 -wells 
immunoplate. The concentration of coating antigen Sal B-HSA was 0.1 g/mL. It was 
then treated with 300 L of 5% SPBS for 1h to decrease non-particular adsorption. Fifty 
microliters of different concentrations of samples dissolved in 5% methanol were 
combined with 50 L of the MAbs solution for 1h. The plate was washed three times 
with PBST and the antibody was joined with 100 L of 1000-fold diluted solution of 
POD-anti-mouse IgG for 1h. In the wake of washing the plate three times with PBST, 
100 L of substrate solution was added to each well and then incubated for 15 min. 
Absorbance at 405 nm was measured utilizing a microplate reader. All reactions were 
done at 37 ℃ . The Fig. 4 shows the icELISA procedures which is followed in the whole 
dissertation.  
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Fig. 4: Protocol of indirect competitive ELISA 
 
 The CRs of the MAbs with different compounds were evaluated and ascertained 
utilizing the strategy for Weiler and Zenk, as takes after:  
 
 
2.9.  Intra and inter assay variations of icELISA 
 Six concentrations of Sal A, were arranged and analyzed by a formerly portrayed 
icELISA utilizing antibodies. Six repeat analyses of each solution were performed 
inside one plate, and intra assay variation was controlled by RSDs of these data. The 
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icELISA for the same six concentrations of Sal A was performed for three consecutive 
days, and inter assay variat ion was controlled by RSDs of data between the plates.  
 
2.10  Recovery of compound from sample 
 Different concentration of Sal A was added to dried powdered leaf of S. 
divinorum  (30 mg). The measure of Sal A in the unspiked test was resolved to be 12.69 
g/mg dry wt. by icELISA. Three concentrations of Sal A (10, 20, 40 g/mg dry wt.) 
was spiked into powdered samples of S. divinorum. In the wake of drying the spiked 
samples, they were extracted by the same methodology as portrayed in the above section 
and the measure of Sal A in every specimen was controlled by an icELISA. The recovery 
rate was figured from the deliberate sum and the additional Sal A in the same 
concentration ranges as follows:  
 
 
3. RESULTS AND DISCUSSION 
 
3.1.  Direct determination of hapten numbers of the hapten-carrier conjugates 
by MALDI-TOF-MS 
Sal A does not have immunogenicity and does not possess a functional group in 
the molecule such as carboxyl or amino group. Thus, I had to synthesize an 
appropriate hapten, and then conjugate it to a protein to prepare an immunogen. Sal 
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B, which is closely related to Sal A, has a hydroxyl group and is an expedient 
compound which is modified by a reaction with succinic anhydride to obtain hemi-
succinate. Sal B hemi-succinate was successfully prepared, and then coupled with 
BSA by the carbodiimide method (Fig. 2). 
 
 Fig. 5 shows the determination of Sal B-BSA conjugates, by the matrix-assisted 
laser desorption/ionization time of flight mass spectrometry  (MALDI-TOF-MS) to 
validate its hapten number as described previousl y. The broad peak of Sal B-BSA in 
MALDI-TOF-MS was increased from around m/z 66,433 to 75,901 whereas the 
molecular weight of BSA and Sal B were 66,433 and 390 respectively. The calculated 
value of the Sal B in the conjugate was 24 molecules which indicates that Sal B -BSA 
could be used as immunogen because it had sufficient hapten numbers to raise anti-Sal 
A antibodies. Sal B-HSA was also prepared and the hapten number was determined to 
be 25 in the same way as Sal B-BSA.  
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Fig. 5: Direct determinations of hapten number of Sal B-BSA conjugates by MALDI-
TOF-MS 
 
3.2.  Production and characteristic of MAbs against Sal A 
The splenocytes of the hyper immunized BALB/c mouse , which were immunized 
with Sal B-BSA, were fused with SP2/0 myeloma cells following the procedures 
established herein (Chavkin, C.; 2004). A hybridoma producing MAb reactive to Sal 
A were successfully obtained from checking different series of screenings with 
icELISA. The MAb, referred to as 3D5, was successfully obtained and its subtype 
was classified as IgG2b having k light chains. 
 
3.3.  Establishment of icELISA using MAb 3D5 
To study the icELISA, an appropriate opt imum concentration of MAb 3D5 was 
measured by the indirect ELISA. The optimal concentration of MAb 3D5 was 333 ng/mL 
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which was selected for the icELISA.  
The icELISA was developed using the concentration of MAb and the ELISA plates 
were coated with 0.1 g/mL of Sal B-HSA. Fig. 6 shows the standard curve of Sal A in 
the icELISA. The result shows the sensitivity of the assay having the linear range from  
0.156 to 1.25 g/mL with R2= 0.9967. The results also show the MAb 3D5 recognized 
Sal A and other salvinorins.  
 
 
Fig. 6: Standard curve for Sal A in icELISA using MAb 3D5 
 
The specificity of MAb 3D5 was determined by the cross reactivity (CR) to 
other Sal A related compounds utilizing the icELISA and figured by utilizing the 
equation created by Weiler and Zenk (Weiler and Zenk; 1976). As Fig. 7 shows CRs of 
the MAb against Sal A and its related compounds; it recognized various salvinorins. In 
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contrast to Sal A (CR: 100%), CRs for salvinorin B, C, D, E and F are <0.084, 26.2, 
9.79, 9.33 and 10.3%, individually. Moreover, I additionally analyzed 4 kinds of 
synthesized salvinorin derivatives having a different side chain at the C2 position for 
this characterization as listed in Fig. 7. MAb 3D5 can react with these compounds 
except benzoyl-salvinorin. Considering their structural similarity to Sal B hemi-
succinate utilized as an immunogen, its specificity must be influenced by the succinyl -
group at C2 in the molecule as well . From the point of view of the low CRs of MAb 
3D5 against salvidivins, the furan ring at C12 plays  a fundamental part in its antigen 
and antigen interaction. Moreover, MAb can thoroughly recognize the fundamental 
characteristic structure of salvinorins by the way that the CRs for C8-epi-salvinorin A 
and C2-epi-salvinorin A are decreased to 0.144 and 21.5%, individually. As clarified 
above, MAb 3D5 demonstrates the novel property of just responding to salvinorins, and 
it must be a unique characteristic to be used for the determination of salvinorins in S. 
divinorum . 
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Fig. 7: CRs of MAb 3D5 against Sal A and structure related compounds  
 
3.4.  Variation and accuracy of the icELISA using MAb 3D5 
Inter and intra assay precisions of the icELISA utilizing MAb 3D5 were investigated. 
Intra assay accuracy was assessed by a variety of Sal A solutions from well to well (n 
=6) in the same plate and inter assay precision was obtained from data between various 
plates (n = 3). From the results given in Table 1, the maximum relative standard 
deviation (RSD) of intra assay was 3.19%, inter assay was 6.82 %. Both the information 
suffice for exhibiting the exactness of the developed icELISA. 
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Table 1: Inter and intra assay precision of Sal A by the icELISA using MAb 3D5 
 
 
All values are mean ± S.D. for three plates and six replicate wells for each concentration 
within one plate for 3 consecutive days.  
To certify reliability of the icELISA, a recovery experiment was performed. After 
spiking S. divinorum samples with Sal A at amount of 10-40 μg/mg dry wt., the sample 
solutions were prepared and Sal A concentration in each sample was determined by the 
developed icELISA. Table 2 demonstrates that high Sal A recoveries in this analysis 
which were indicated, in the range of 96.2 to 104.1%. Every recoveries of spiked Sal A 
from each sample were acquired at a level of nearly 100%, demonstrating great 
reliability of this system, affirming this method to be valuable for the reliable 
determination of salvinorins in a plant sample. 
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Table 2: Recovery of Sal A from spiked samples using the icELISA 
 
 
Recovery (%) = (measured amount – 12.6 / added amount) × 100. 
 
4. CONCLUSION 
To prepare an immunogen, Sal B hemi-succinate was synthesized and conjugated 
with a free amine in BSA to acquire Sal B-BSA conjugate. The hyper–immunized 
BALB/c mouse injected with Sal B-BSA yielded splenocytes that were fused with SP2/0 
myeloma cells by general protocols utilizing HVJ envelop. Hybridoma secreting MAb 
referred as to 3D5 reactive to Sal A was obtained. MAb 3D5 was classified as IgG2b 
that had light chains. The MAb shows CRs for various Sal A related compounds. 
Therefore, the optical concentration of anti-Sal A for icELISA was characterized to be 
333 ng/mL. Utilizing the standard curve, a calibration curve for the determination of 
Sal A could be obtained, ranging from 0.156 to 1.25 μg/mL.  
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CHAPTER 3 
 
Development of a Combined Technique Using a One-Step 
Immunochromatographic Assay and ELISA for the Rapid Detection of 
Sal A 
 
1. INTRODUCTION 
The utilization of immunochromatographic assay (ICA) technology has turned into 
an essential analytical method for the quick and accurate immunochemical detection of 
drugs. Such ICA gives fast and sensitive detection of low atomic weight analytes  with 
competitive immunoassays. Likewise, a combined immunoassay comprises of ICA and 
icELISA for analysis of salvinorins in S. divinorum  was reported in Chapter 3.  
Fig. 8 shows a focused competitive immunoassay utilizing the MAb as the detector 
antibodies (Fig. 8). The sample solution was applied to the sample pad, and Sal A in 
solution were bound to the detection reagent (i.e. colloidal gold conjugated of MAb 
3D5) present in the conjugate pad. The respective free detection reagent or free Sal A 
migrated on the strip and passed over the capture reagents (Sal B-HSA) where any 
detection reagent that was free of analytes bound the appropriate capture reagent at the 
individual capture zone while the control reagent (anti-goat mouse IgG) would bind to 
MAb 3D5 at the control spot. Color showed up at the both the capture and control spots 
if the sample contained no Sal A (negative sample), while no color was observed at the 
capture spot when the sample contained Sal A (positive sample).  
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Fig. 8: (a) The strip test is based on a competitive immunoassay methodology using 
MAb 3D5 as the detection reagent. (b) Color only appears in the C if a sample is positive 
for salvinorins (c) color appears in both T and C if sample is free of Sal A 
 
2. MATERIALS AND METHODS  
 
2.1.  Materials 
All materials and chemicals used in chapter 2 were also used in chapter 3. Colloidal 
gold with an average particle diameter of 15 nm was purchased from Tanaka Technical 
Center (Kanagawa, Japan).  
 
2.2.  Sample preparations 
 Same samples from Chapter 2 were used in Chapter 3. 
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2.3.  Preparation of antibody-colloidal gold 
The colloidal solution with 2% potassium carbonate solution was adjusted to pH 
9.0. The 3D5 (10 μg) was dissolved in 1 mL of the colloidal solution and stirred gently 
at room temperature for 15 min. The conjugate was balanced out with BSA in 0.1 M 
Tris-HCl buffer (pH 8.0) and conformed to definite concentration of 1% BSA. The 
mixture solution was incubated for 1 h at room temperature and centrifuged at 12,000 
rpm for 10 min. The supernatant was disposed and the pellet was re-suspended in 1% 
BSA in 0.1 M Tris–buffer (pH 8.0). The concentrated MAb-gold conjugate in 1% BSA 
was put away at 4 °C until required. The detection reagent contained 10 μL of 3D5 
conjugated colloidal gold, 15 μL of 10% sucrose in water, 7 μL of 1% Tween 20 in water, 
and 8 μL of water. An  aliquot (10 μL) of the detection reagent was applied to the glass 
fiber conjugate pad (Millipore Temecula, CA, USA) and the pad was dried for 2 h at 
room temperature before putting it on the test strip. 
 
2.4.  Preparation of capture reagent 
 The same capture reagent Sal B–BSA and Sal B–HSA conjugates from Chapter 
2 were utilized here. Anti-mouse IgG rabbit (whole molecule) was utilized as the control 
capture reagent.  
 
2.5. Preparation of chromatographic strip 
0.1 μg of Sal B-HSA conjugates (test) and 1 μg anti-mouse IgG rabbit (control) 
capture reagents were applied to a strip of nitrocellulose membrane (Millipore Temecula, 
CA, USA) at the target zone and the control zone, respectively. It was dried at room 
 22 
 
temperature for 1 h. At that point, the membrane was submerged in 1% BSA containing 
PBS and incubated with stirring at room temperature for 2 h. The membrane was washed 
twice with PBS containing 0.05% Tween 20 (PBST) for 15 min. Subsequent to drying, 
the membrane was cut into single test strips. Every test st rip was gathered with the 
nitrocellulose membrane, an absorbent pad, the detection reagent in the conjugate pad 
and a sample solution. The sample solution (400 μL) was transfer red to a tube into 
which the lower edge of the test strip was dipped. The samples migrated upwards and 
the results of the test were perused after 15 min.  
 
3. RESULTS AND DISCUSSION 
 
3.1.  Immunochromatographic strip test 
The ICA depended on a focused competitive immunoassay, utilizing the MAb as the 
detector antibody. After the test solution was applied to the strip, the fluid flows upward 
by capillary activity and responds to the dried colloidal gold MAb 3D5 on the conjugate 
pad, which also contains detection reagent.  
Sal A bound to MAb 3D5, free Sal A, and MAb 3D5 migrated upward along the  strip 
with the sample solution. Addition of BSA (1%) in PBS as a blocking solution decreased 
non-particular adsorption and immobilized the capture reagents on the nitrocellulose 
membrane. In order to remove non-adsorbed blocking agent, PBST was used to wash 
the membrane and to achieve uniform re-wetting of the membrane. The solubility of the 
detection reagents on the conjugate pad were increased by addition of sucrose (10%) 
with 1% Tween-20 to the detection reagent to increase solubility.  
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Fig. 9 shows analysis of a standard Sal A solution, with 20% methanol as a negative 
control, in the developed ICA. Color appeared at both the target  and control zones when 
the sample was free of Sal A (negative sample).Whereas no color appeared at the target 
spot zone, while the control spot zone being constantly visible, when the sample 
contained Sal A (positive sample). The proper sample volume size was 400 L, and the 
assay need be finished in around 10–15 min. Fig. 10 demonstrates that detection limit 
for Sal A utilizing the strip test was 0.625 g/mL, which was seen on visual signs.  
 
Fig. 9: Visual indications obtained using immunochromatographic strip test for Sal A 
showing (A) a positive sample (Sal A, 50 g/mL), (B) a negative sample 
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Fig. 10: Determination of the detection limit for the ICA of Sal A  
 
3.2.  Analysis of S. divinorum and several Lamiaceae plants by the ICA and 
icELISA 
On the other hand, methanol was also used as an extraction solvent to prepare sample 
solutions for other Salvia species such as S. farinacea, S. patens, S. microphylla , as 
well as  Lamiaceae plants such as Ocimum basilicum and Rosmarinus officinalis,  which 
are available for sale as common plants and do not contain Sal A. Consistent with this, 
no Sal A was detected in these samples (Fig. 11 Lanes 6–10). Based on this result, it is 
likely that other substances present in complex samples do not affect analysis of Sal A 
by ICA. 
MAb 3D5 has the fascinating property that it recognizes Sal A as well as different 
salvinorins. Our results demonstrated that diluted solutions of the samples contained 
more than 9.72 μg/mg, based on visua l inspection, as shown in Fig. 11 (paths 1–5). 
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Based on these results, the concentration of these  S. divinorum  samples was computed 
to be > 16.7 μg/mg. No Sal A was distinguishable in the samples (Fig.  11 Lanes 6-10). 
Thus, different substances present in complex samples do not influence ICA analysis. 
Using this system, Sal A was detectable from 333 ng/mL to 1.25μg/mL (Fig. 6).  
 
Fig.11: Visual indications obtained using immunochromatographic strip test for Sal A 
showing Lane’s 1-5 S. divinorum and lane 6-10 Salvia spp. (S. farinacea, S .patens, 
S .microphylla, Ocimum basilicum, and Rosmarinus officinalis) 
 
The samples were examined by the icELISA and ICA methods described above. Table 
3 shows the results of quantitative analysis of these samples, based on the system 
utilizing Sal A as a standard preparation. As expected, salvinorins were identified only 
in S. divinorum . With regard to the quantitative data, the content of salvinorins in S. 
divinorum was between 9.72 and 16.7 μg/mg dry wt., consistent with previous studies 
of this plant. This result reveals that the total sum of different salvinorins is too sm all, 
and that MAb 3D5 has a weaker affinity for the alternative salvinorins than for Sal A.  
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Table 3: Determination of salvinorins by using icELISA and visual indication of ICA 
 
Data are mean ± S.D. from triplicate analyses for each sample.  
N.D.: not detected 
+: Presence of Sal A  
-: Absence of Sal A 
 
4. CONCLUSION 
In this research, I successfully prepared ICA utilizing MAb 3D5 against Sal A and 
described this MAb to show novel acknowledgment to salvinorins. As indicated by the  
results, the limit of detection for Sal A utilizing strip test was 9.72 μg/mg dry wt. in S. 
divinorum , and other Salvia spp.  for example, S. farinacea, S. patens, S. microphylla 
and Lamiaceae plants (Ocimum basilicum , and Rosmarinus officinalis) were negative 
for the ICA. The assay could be finished in around 10-15 min. Moreover, the ICA is 
basic, fast, and compelling. The icELISA and ICA was accepted by analysis of plant 
materials including S. divinorum, and it is presumed that it was adequately touchy, exact 
and dependable to be utilized as a separation technique.  
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CHAPTER 4 
 
Production of Monoclonal Antibody against Wogonin Glucuronide and 
Its Application in ELISA 
 
1. INTRODUCTION 
As a powerful traditional Chinese medicinal herb, Scutellaria baicalensis  Georgi (S. 
baicalensis, Chinese Skullcap) (Fig. 12) has been utilized for a huge number of years 
for antifebrile and detoxification purposes. The roots of S. baicalensis  are referred to 
Huang-Qin in China and to Ogon in Japan, and is a noteworthy ingredient of Kampo 
medicines.  
 
 
Fig. 12: Scutellaria baicalensis  
Wogonin glucuronide (Wogonin 7-O--D-glucuronide, Wgn, Fig. 13) is one of the 
major bioactive flavones among more than 30 kinds of flavonoids, for example, 
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baicalein, baicalin, wogonin, oroxylin A, oroxylin A glucuronide, and skullcapflavone 
II in S. baicalensis  (H.B. Li, 2004; C.R. Li, 2009; K. Nishikawa, 1999).  
 
Fig. 13: Chemical structures of major bioactive flavones in S. Radix  
 
Latest studies demonstrate that Wgn has anti-hypersensitive, mitigating, anti-HIV, 
anti-tumor, anti-oxidant, anti-viral activities, and free radical scavenging effects. It is 
likewise effective in the central nervous system (CNS) and its viability in CNS issue. 
For example, uneasiness, epilepsy, and memory and learning disability, consideration 
shortage hyperactivity issue and neurotoxicity have been reported (A. Koda, 1977; B.Q. 
Li, 2000; J.A. Wu, 2001; T.K. Konoshima, 1992; S. Ikemoto, 2000; Z. H. Gao, 2001; 
H.C. Ahn, 2001; J.F. Liao, 2003; H.G. Park, 2007; J. Xu, 2000) .  
Analytical methodologies for Wgn have been performed by TLC, GC/MS, HPLC 
with ultraviolet, HPLC with electrochemical detection, UPLC, LC-MS, UPLC-ESI-
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MS/MS were applied to show high sensitivity in the pharmacokinetic investigation of 
Wgn (C.R. Li, 2011; Y.H. Kim, 2006; H.J. Chung, 2012; L. Zhang, 2005; L. Zhang, 
2006; W. Liu, 2010; Y.C. Hou, 2011) . The purpose behind this present study is to 
prepare monoclonal antibodies against  Wgn and develop an icELISA, which could be 
applicable for the quality control of S. Radix. 
 
2. MATERIALS AND METHODS 
 
2.1.  Materials 
 BSA and HSA were obtained from Sigma (Steinheim, Germany). Freund`s 
complete and incomplete adjuvants were purchased from Difco (Detroit, USA). POD-
anti mouse IgG (Whole molecule) were obtained from MP Biomedical (Solon, OH, 
USA). HRP labelled anti -T7-Tag conjugate was purchased from Novagen (San Diego, 
CA, USA). Anti-mouse IgG (Fab specific)-POD created in goat was obtained from 
Sigma-Aldrich (St. Louis, MO, USA). All other chemicals and organic solvents were 
standard commercial products of analytical -reagent grade. 
 
2.2.  Sample preparations 
 Samples of various S. Radix were obtained from Tochimototenkaido Co., Ltd. 
(Osaka, Japan), Takasago Yakugyo K.K. (Osaka, Japan), Daido Corp. (Osaka, Japan), 
and Yamada Corp. (Osaka, Japan). Kampo medicines were purchased from Tsumura and 
Co. (Tokyo, Japan).  
Thirty milligrams of each S. Radix, including a sample cultivated in the herbal 
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garden of Kyushu University were weighed, cut into little pieces, and ground into fine 
powder. Each sample was extracted with 0.5 mL methanol using a sonicator for 10 min. 
The extract was subsequently centrifuged at 12,000 rpm for 15 min and transferred into 
a glass test tube. This extraction step was done three times totally and the supernatants 
were mixed to generate a sample solution. Subsequently, the solution was evaporated 
to yield the extract. The extract was dissolved in methanol (1 mL) and diluted for ELISA 
and HPLC analysis.  
 
2.3.  Isolation of different flavonoids and synthesis of wogonin glucosides 
 The S. Radix (100 g) were extracted successively with methanol (0.5 L) utilizing 
an ultrasonic bath for 5 h. The extract was then centrifuged at 6,500 rpm for 10 minutes 
and the supernatant was changed to a test tube. The residue was extracted with the same 
way more than two times and each of the supernatants were mixed to get the methanol 
extract. The combined extract was evaporated under reduced pressure to give 24.50 g 
extract. The methanol extract of S. Radix was subjected to column chromatography on 
ODS-silica gel eluted with 50% methanol, and re-chromatographed on ODS-silica gel 
eluted with  50% methanol twice to yield Wgn and oroxylin A glucuronide. The 
methanol eluate fraction was further subjected to column chromatography on ODS-
silica gel eluted with 70% methanol, and re -chromatographed on ODS-silica gel eluted 
with 70% methanol twice to yield wogonin, oroxylin A and skullcapflavone II. 
Progressive extraction of the S. Radix was applied to repeated column chromatography 
to isolate the compounds. The yield of compounds which are wogonin (26.2 mg), Wgn 
(20.6 mg), oroxylin A (13.1 mg), oroxylin A glucuronide (13.1 mg), skullcapflavone II 
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(7.41 mg).  
Dried Wgn (15.42 mg) was totally dissolved in DMF before being included with 
potassium carbonate in water. Aliquot (2.326 mg) was added in a solution of Wgn in 
chloroform which was then added and stirred at 43°C for 24 h. It took after by silica 
gel column with hexane and ethyl acetate acid derivation to get 57.0 mg of intermediate 
compound. Further 61.52 mg of sodium methoxide was dissolved in 2.27 mL of 
methanol, and the mixture was stirred into vial content of 22.78 mg of intermediate 
compounds. The mixture was stirred and followed by TLC.  
The developed reactions finished once the starter  vanished and framed one pink 
spot on baseline. The product was 9.2 mg. The structure of wogonin, Wgn, oroxylin A, 
oroxylin A glucuronide, skullcapflavone II and wogonin glucopyranoside were 
identified using , UV, ESI/MS, 1H-NMR and 13C-NMR. The data was consistent with 
recent experiments. The purity level of all compounds exceeded 99% as determined by 
HPLC. 
 
2.4.  Synthesis of Wgn conjugates  
 The synthesis of Wgn–conjugates was performed as described in Chapter 2 with 
some modifications. The Wgn was hapten and conjugated to BSA and HSA as an 
immunogen and coating specialist, individually. The amount used in this exp eriment 
were Wgn (5.0 mg, 0.023 mmol) and EDC (6.0 mg, 0.031 mmol). Wgn -BSA conjugate 
(6.2 mg) and Wgn-HSA conjugate (6.3 mg) was obtained respectively (Chapter 4, 5, 
and 6) 
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Fig. 14: Synthesis of Wgn-Carrier protein conjugates  
 
2.5.  Determination of hapten number in Wgn conjugates by MALDI -TOF-MS  
 The hapten numbers of Wgn-BSA, and Wgn-HSA conjugates were dictated by 
MALDI-TOF-MS. A little sum (1-10 pmol) of an antigen conjugate was mixed with a 
103-fold molar abundance of sinapinic acid in an aqueous mixture which contain 0.10% 
tri-fluroacetic acid. The mixture solution was subjected to an elite MALDI -TOF-MS 
system, Autoflex III (Brucker Daltonics, Bremen, Germany). The data and information 
were analyzed utilizing flex analysis 3.0.92.  
 
2.6.  Immunization, hybridization, and production of MAb  
 The production of anti-Wgn–MAb was performed as described in Chapter 2 with 
some modifications. Wgn-BSA was used an immunogen. I prepared MAb by a general 
fusion protocol using PEG. Successfully, one hybridoma cell line producing MAb 
reactive to Wgn (referred to as 315A) was produced. 
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2.7.  Purification of MAb 
 MAb secreted from hybridoma was refined utilizing a Protein G FF column (0.46 
cm x 11 cm, GE Health Care, Uppsala, Sweden). The cultured medium (500 mL) 
containing IgG was changed in accordance with pH 7.0 with 1 M Tris -HCl solution pH 
9.0 and applied to the column. The column was washed with 10 mM phosphate buffer, 
pH 7.0. Adsorbed IgG was eluted with 100 mM citrate buffer, pH 3.0. The eluted IgG  
was neutralized with 1 M Tris-HCl (pH 9.0), dialyzed three times against H 2O, and 
lyophilized to give 7.3 mg MAb 315A. 
 
2.8.  Indirect ELISA using coating antigen   
 The reactivity of the MAb to coating antigen was dictated by indirect ELISA. 
The 96-wells immunoplate (Maxisorb, Nalgene Nunc, and Roskilde, Denmark) was 
coated with 100 L of antigen in carbonate buffer (50 mM, pH 9.6) and incubated at 
37 ℃  for 1h. The concentration of coating antigen Wgn -HSA is 2 g/mL. The plate 
was washed three times with 0.05% Tween 20 containing PBS (PBST). It  was then 
treated with 300 L of PBS containing 5% skim milk (SPBS) for 1h to decrease non -
particular adsorption. At that point, the plate was washed three times with PBST and 
responded with 100 L of testing antibodies for 1h. The plate was washed again with 
PBST three times and after that, MAbs was joined with 100 L of 1000-fold diluted 
solution of POD-labelled anti-mouse IgG (Biomedical, Cappel Products, CA) for 1h. In 
the wake of washing the plate three times with PBST, 100 L of substrate solution, 0.1 
M citrate buffer (pH 4.0) containing 0.003% H 2O2 and 0.3 mg/mL 2, 2`-azino-bis (3-
ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) (Wako, Osaka, Japan) 
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were added to each well and incubated for 15 min. Absorbance at 405 nm was measured 
by a microplate reader (ImmunoMini, Nunc). All reactions were completed at 37 ℃ .  
 
2.9.  icELISA using Wgn MAbs 
 The procedures for the icELISA were followed by the coating antigen (100 L)  
dissolved in  50 mM carbonate buffer (pH 9.6) which was adsorbed to the 96-wells 
immunoplate. The concentration of coating antigen Wgn -HSA is 2 g/mL. It was then 
treated with 300 L of 5% SPBS for 1h to decrease non-particular adsorption. Fifty 
microliters of different concentrations of samples dissolved in 5% methanol were 
combined with 50 L of the MAbs solution for 1h. The plate was washed three times 
with PBST and the antibody was joined with 100 L of 1000-fold diluted solution of 
POD-anti-mouse IgG for 1h. In the wake of washing the plate three times with PBST, 
100 L of substrate solution was added to each well and incubated for 15 min. 
Absorbance at 405 nm was measured utilizing a microplate reader. All reactions were 
done at 37 ℃ . 
 The CRs of the MAbs with different compounds were evaluated and ascertained 
utilizing the strategy for Weiler and Zenk, as takes after:  
 
 
 
 
CR (%) = 
IC50 for Wgn 
IC50 for compound under investigation  
X 100 
 35 
 
2.10. Intra and inter assay variations of icELISA 
 Six concentrations of Wgn were arranged and analyzed down by a formerly 
portrayed icELISA utilizing antibodies. Six repeat analyses of every solution were 
performed inside one plate, and intra assay variation was controlled by RSDs of these 
data. The icELISA for the same six concentrations of Wgn was performed for three 
consecutive days, and inter assay variation was controlled by RSDs of data between the 
plates. 
2.11. Recovery of compound from sample 
 Different concentration of Wgn were added to dried powdered l eaf of S. Radix  
(30 mg). The measure of Wgn in the unspiked test was resolved to be 1 22.69 g/mg 
dry wt. by the icELISA. Three concentrations of Wgn (10, 20, 30 g/mg dry wt.) were 
spiked into powdered samples of S. Radix . After drying the spiked samples,  they were 
extracted by the same methodology as described previously and the measure of Wgn in 
every sample was defined by an icELISA. The recovery rate was calculated from the 
measured amount and the additional Wgn in the same concentration ranges as follows:  
 
  
 
2.12. HPLC instruments and conditions  
The HPLC system utilized is comprises of a SPD-20A Shimadzu Prominence 
UV/VIS detector with 254 nm and a HP proBook 42305 computer connected to Gilson 
805 Manometric Module pump. The analytical column was Cosmosil 5C18-MS II column 
Recovery (%) = 
Measured amount -19.52 
Added amount 
X 100 
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(4.6 mm i.d. x 150 mm, Nacalai Tesque, Kyoto, Japan) kept up at roo m temperature. 
The mobile phase consisted of CH3CN-H2O (3:7, v/v) containing 50 mM phosphoric 
acid. The flow rate was 1.0 mL/min. 
 
3. ESULTS AND DISCUSSION 
 
3.1.  Direct determination of hapten numbers of the hapten carrier protein 
conjugates by MALDI-TOF-MS 
Wgn has a carboxylic group in its molecule, can be conjugated with a protein via 
carbodiimide system. In this manner, Wgn was conjugated with BSA as a carrier protein 
(Fig. 14). Since an adequate hapten number of a conjugate is essential to raise an 
immune response, analysis of Wgn-BSA conjugate by MALDI-TOF-MS, which is useful 
for exact determination of a hapten number of a conjugate, was performed as reported 
previously (Gruber, J.W.; 1999 and Cone, E.J.; 1989).  
A broad peak of Wgn -BSA in the MALDI-TOF-MS range was observed in Fig. 15. 
Based on the peak around m/z 68,858 and the molecular weights of BSA and Wgn 
(66,433 and 460 individually), 5 molecules of Wgn was conjugated to BSA in the case 
of this specific conjugate. MALDI-TOF-MS analysis showed that the conjugates had 
adequate hapten numbers and could show immunogenicity to raise anti-Wgn antibodies. 
Likewise, Wgn-HSA, which was utilized as a solid-phase antigen in ELISA, was 
additionally analyzed by the MALDI-TOF-MS range and its hapten number was 
calculated to be 7.  
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Fig. 15:  Direct determination of the hapten number of Wgn-BSA conjugates by 
MALDI-TOF-MS 
 
3.2.  Production and characteristics of MAbs against Wgn 
These splenocytes from the mouse immunized with Wgn-BSA were fused with SP2/0 
myeloma cells using he system reported previously (Chavkin, C.; 2004). Finally,  a 
hybridoma cell secreting anti-Wgn MAb in the positive well was selected and cloned. 
Effectively, one hybridoma cell line producing MAb reactive to Wgn (referred to as 
315A) was obtained and characterized under the classification of IgG1, which have κ 
light chains.  
 
3.3.  Establishment of icELISA using MAb 315A 
To set up the icELISA, an optimal concentration of MAb 315A was determined by 
indirect ELISA. Accordingly, the optimal concentration of MAb 315A for icELISA was 
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characterized to be 1.56 g/mL which gave an absorbance of around 0.8 - 1.0 at 405 
nm.  
 
 
Fig. 16: Standard curve for Wgn based on the icELISA using MAb 315A  
 
Under the conditions, an icELISA was performed to describe Wgn. While applying 
the MAb 315A, two fold serial dilutions of Wgn were applied to the micro immunoplate 
and contended with the binding of MAb 315A to Wgn-HSA. After treatment with a 
secondary antibody and the addition of a substrate to the plate, the gradation of color 
development was recognizable relying upon an increase in the concentration of Wgn to 
make standard curve. Based on the standard and calibration curve, the determination of 
Wgn could be prepared, ranging from 1.56 to 25 μg/mL as appeared in Fig . 16.  
The specificity of MAb 315A was indicated by the CRs to other Wgn related 
compounds which was calculated using the icELISA. It was calculated by utilizing the 
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equation created by Weiler and Zenk. As Table 4 shows CRs of the MAb 315A against 
Wgn and its related compounds, it perceives Wgn, along with different flavonoids. 
Comparing with Wgn (CR: 100%), CRs for wogonin, baicalein, baicalin, luteolin 
glucuronide, apigenin glucuronide, daidzein, genistein, oroxylin A, oroxylin A 
glucuronide and skullcapflavone II are comparatively low under 2.07%. However CR 
for wogonin glucopyranoside is 27.09% as the glycoside linkage of Wgn is crucial for 
recognition of the antibody.  
 
Table 4: CRs of MAb 315A against Wgn and structurally related compounds  
 
 
Variation and accuracy of the icELISA using MAb 315A, inter and intra assay 
precisions were studied. Intra assay accuracy was assessed by variety of the 
determination of Wgn from well to well (n = 6) in the same plate. The inter assay 
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precision was obtained from different plates (n = 3). Using the results from Table 5 the 
most extreme relative standard deviation (RSD) of intra  assay and inter assay was found 
to be 4.27%, and 8.31 %, respectively. Both the data suffice for showing the accuracy 
of the developed icELISA.  
 
Table 5: Inter and intra assay precision of the analytical method for Wgn using the 
icELISA 
 
 
To attest reliability of the icELISA, a recovery experiment was performed. After 
spiking different samples with Wgn at amount of 10-30 μg/mg dry wt., the sample 
extracts were prepared. The Wgn content in each sample was determined using the 
developed icELISA. Table 6 demonstrated the excellent Wgn recoveries in this analysis 
ranging from 96.66 to 98.16%. The recoveries of spiked Wgn from each sample were 
obtained at a level of nearly 100%, demonstrating each unwavering quality of this 
system, affirming this technique to be valuable for the reliable determination of Wgn 
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in various plant samples. 
 
Table 6: Recovery of Wgn from spiked samples using the icELISA 
 
Recovery (%) = (measured amount – 19.52 / added amount) × 100.  
 
3.4.  Analysis of S. Radix Georgi by icELISA using MAb 315A 
The MAb 315A prepared in this study shows a novel characteristic that it reacts with 
Wgn and wogonin 7-O--D-glucopyranoside. The MAb 315A was applied as a 
quantitative method of Wgn in Scutellia radix. Table 7 shows the results of the 
quantitative analysis for various samples. As expected, Wgn was only detected in 
Scutellariae radix. Regarding the quantitative data, the Wgn content of Scutellariae  
radix was determined to range from 17.71–23.13 μg/mg dry wt., and  the data obtained 
by HPLC were 17.13–21.43 μg/mg dry wt., which showed a good correlation between 
reported HPLC data. From this data, it was determined that very low concentration of 
wogonin 7-O--D-glucoside in S. radix did not affect the quantitative data of Wgn in 
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the samples by the icELISA using anti -Wgn MAb 315A.  
 
Table 7: Determination of Wgn in S. Radixes by the icELISA using MAb 315A  
 
*: The root of S. baicalensis  cultivated in the herbal garden of Kyushu University.  
 
4. CONCLUSION 
To prepare an immunogen, Wgn was conjugated with a free amine in BSA to acquire 
Wgn-BSA conjugate. Hybridoma secreting MAb referred to MAb 315A was obtained. 
The antibody isotype was IgG1 having light chains. I prepared an ideal MAb to be 
applicable to the icELISA for the determination of Wgn in S. Radix. Because of its 
effective cost-performance, rapidity, simplicity, newly developed icELISA system 
utilizing the MAb could be valuable as a quality control technique for S. Radix. 
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CHAPTER 5 
 
Study of different peptide linker lengths of single chain variable 
fragment against wogonin glucuronide  
 
1. INTRODUCTION 
In general, MAbs are popular tools in biological investigation, because of their high 
specific affinity (Weiler et al., 1990). Its recombinant DNA technology along with 
continually expanding data on the genetics and structure of immunoglobulin, have l ed 
to the production of antibodies in Escherichia coli  (E.coli) (Better et al., 1998) and 
different organisms (Jost et al., 1994; Bei et  al., 1995; Davis et al., 1991; Whitelam et 
al., 1994). Recombinant antibodies offer potenti al favorable circumstances for 
production, capacity to adjust properties through mutagenesis and data on immune 
response target cooperation.  
The production of the hybridomas that produce MAb against MAb 315A and its 
application in ELISA for determination of Wgn were described in Chapter 4. It is time 
taking and laborious to get MAb. Besides, certain methods required to manage the 
hybridoma cells need to be secluded, as the microorganisms could easily contaminate 
the environment and bring illness to humans. However, recombinant DNA technology 
has empowered the production of single-chain variable fragment (scFv) antibodies, 
which have heavy chain variable region (VH) and light chain variable region (VL) with 
different length of flexible peptide linker (Gly4Ser)n in bacteria (n=3, 5, and 7). In 
comparison, the scFv showed significantly reduced size (around one-6th of unique) to 
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the full length IgG molecule.  
The scFv system has become one of the most popular techniques in antibody 
engineering. It has been exploited in research, therapeutic, and different  applications 
including bio sensors for recognition of target molecules (Kortt et al., 2001), cytokines 
for immunotherapy (Penichet et al., 2001). It is also used in radioisotopes for disease 
imaging (Adams et al., 2000) in light of the fact that counter acting agent creation with 
microbes is much less difficult, less expensive, and speedier than with hybridomas  once 
the development of recombinant antibodies is built up. In this manner, our research 
facility has been centered on development of scFv against bioactive plants secondary 
metabolites, for example, taxol, artemisinin, (Paudel MK et al.,) for quality control of 
their host plants.  
Construction, expression, characterization of scFv against (Wgn-scFv) expressed in 
E.coli and its potential use in the icELISA as an alternative tool for MAb 315A are 
shown in this Chapter 5. To overcome the disadvantages of MAb preparation using 
hybridomas, small sized antibodies against Wgn was genetically engineered by 
construction of scFv.  
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Fig. 17 Structure of IgG antibody and scFv antibody 
2. Materials and Methods 
 
2.1.  Reagents and standards  
Peroxidase (POD)-labeled anti-mouse IgG (Fc) was purchased from MP Biomedicals 
(Santa Ana, CA, USA). POD-labeled anti-T7-Tag conjugate was purchased from 
Novagen (San Diego, CA, USA). Ex Taq DNA polymerase, Prime STAR HS DNA 
polymerase, and DNA reaction enzymes were acquired from Takara (Kyoto, Japan). 
Primers were obtained from Fasmac (Kanagawa, Japan). All materials and chemicals 
used in Chapter 4 were also used in Chapter 5.  All other compounds and natural 
solvent were of analytical reagent grade.  
 
2.2.  Sample preparation 
The same plant samples used in Chapter 4 were also used in Chapter 5.  
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2.3.  Preparation of antigen conjugates 
The antigen conjugates prepared in Chapter 4 were also used in Chapter 5.  
 
2.4. Strains, media, and plasmid vectors  
E. coli strain JM109 was used to prepare the different plasmid constructs. E. coli  
strain BL21 (DE3) was used to express Wgn–scFvs. Bacteria were cultivated on 
lysogeny broth (LB) medium containing 1% (w/v) polypeptone, 0.5% w/v yeast extract, 
0.5% (w/v) NaCl, pH 7.2. The pMD 20-T vector (Takara, Kyoto, Japan) was utilized for 
developing VH and VL genes, while the pET28a (+) vector (Novagen, WI, USA) was 
used to constructing individual full -length scFv genes.  
2.5.  Construction, expression, and purification of multiform Wgn–scFv genes 
The total RNA (5 µg) was extracted from 3 × 10 6 hybridoma cells (315A) utilizing 
the Sepasol RNA I super reagent (Nacalai Tesque Inc., Kyoto, Japan) as directed by the 
manufacturer. First-strand cDNA was synthesized utilizing random hexamer primers 
(Amersham Biosciences, Buckinghamshire, UK). The VH and VL genes were amplified 
by PCR using established antibody-specific primers (Krebber et al., 1997), and the PCR 
products were cloned into the pMD 20-T vector.  
Specific primers for constructing multiform Wgn-scFv genes were planned from the 
exact sequence of the VH and VL genes. Genes encoding Wgn–scFvs were developed 
in the VH-linker-VL orientation, where several linkers in the configuration of 
(GGGGS)n (n = 3, 5, or 7) were used. Primers for  constructing the multiform Wgn–scFv 
genes are listed in Table 8. As VH- (GGGGS)3-VL (3L), the VH gene was amplified 
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with primers 1 and 3, while the VL was amplified with primers 2 and 4. The genes 
encoding VH and VL were fused in the order VH-(GGGGS)3-VL using splicing by 
overlap extension PCR (SOE PCR) with primers 1 and 2. The VH-(GGGGS)n-VL (n = 
5 or 7) was exclusively named 5L and 7L. Construct 5L was built using the primer pairs 
1, 5 and 2, 6, whereas 7L was built using the primer pairs 1, 7 and 2, 8,  to amplify the 
VH and VL genes. All Wgn–scFv constructs were sub-cloned into the pET28a (+) 
expression vector (Novagen, Darmstadt, Germany) in order to use the hexahistidine 
(His6) epitope tag and T7 promoter present in this vector.  
 
Table 8: Primers used to construct the Wgn-scFv genes 
 
The restriction sites are underlined.  
 
PCR-amplified scFv genes were digested with restriction enzymes and sub -cloned 
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downstream of the His6 and T7 epitope tag sequences in the pET28a expression vector 
to generate the pET28a/Wgn-scFv plasmid. At this point, the pET28a/Wgn-scFv 
plasmid was transformed into E.coli BL21 (DE3) cells.  
The three constructs 3L, 5L, and 7L were all transformed into E. coli  for expression 
and subsequent purification. Transformed  E. coli were cultured in 1 L of LB medium 
containing 50 µg /mL kanamycin at 37°C. Wgn-scFv protein expression was induced 
when the optical densities of the culture at 660 nm achieved 0.6, and isopropyl-β-D-
thiogalactoside (IPTG) (0.5 mM) was added to the culture. After incubating at 37°C for 
12 h, the cells were harvested by centrifugation, re -suspended in 50 mL of 20 mM 
phosphate buffer (PB) (pH 8.2) containing 0.5 M sodium chloride, and lysed with hen 
egg lysozyme (1 mg /mL). The lysate was disrupted by sonication, and centrifuged at 
9,000 rpm for 20 min to prepare soluble and insoluble fractions.  
Insoluble fractions were dissolved in 50 mL of buffer A (20 mM PB containing 8 M 
urea and 0.5 M sodium chloride) and applied to a column (1.0 × 5.0 cm) containing a 
His-binding resin (Novagen) equilibrated with buffer A. After applying the sample, 
non-specifically bound proteins were expelled with 100 mL of buffer A c ontaining 20 
mM imidazole. The exahistidine-labeled recombinant antibodies were eluted with 100 
mL of buffer A containing 500 mM imidazole. The above purification protocol was 
performed for second time. The purity of each recombinant protein was verified by 
SDS-PAGE analysis (Latemmli et al., 1970).  
 
2.6.  Refolding of recombinant anti-Wgn antibodies  
The three recombinant antibodies 3L, 5L, and 7L were refolded under the same 
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conditions as depicted below (Umetsu et al., 2003). The recombinant scFv antibody was 
solubilized in 20 mM PB (pH 8.0), containing 200 mM sodium chloride, and 1 mM 
EDTA and 8 M urea, and refolded taking after the strategies reported by Umetsu et al. 
with slight adjustment. Briefly, the solubilized scFv protein (300 μg /mL, 10 mL) was 
reduced by addition of β-mercaptoethanol (β-ME) (600 μM). At that point, the scFv was 
refolded by steady expulsion of urea by means of stepwise dialysis against 20 mM 
phosphate buffered saline (PBS) containing urea (8, 4, 2, 1, 0.5, 0.25, 0.125, 0 M). At 
the 2–0.125 M urea stages, 400 mM L-arginine and 600 µM reduced and oxidized 
glutathione were added to encourage the formation of disulfide bonds. After stepwise 
dialysis, the refolded scFv arrangement was centrifuged at 9,000 rpm for 20 min at 4°C 
to expel accumulated proteins and was utilized for the ELISA tests as Wgn-scFv. 
 
2.7.  Characterization of Wgn-scFvs by icELISA  
Following the completion of icELISA steps, 100 L of the coating antigen was 
dissolved in  50 mM carbonate buffer (pH 9.6) prior to adsorption to a 96 -well 
immunoplate. The plate was subsequently treated with 300 L of 5% SPBS for 1 h to 
prevent non-specific adsorption. 50 L of different concentrations of Wgn or samples 
dissolved in 5% methanol were combined with 50 L of each scFv solution (100 g 
/mL) for 1 h. The plate was washed three times with TPBS and the antibody was 
incubated with 100 L of 5000-fold diluted solution of POD-conjugated mouse anti-T7 
tag IgG for 1 h. After washing the plate three times with TPBS, 100 L of substrate 
solution was added to every well and incubated for 15 min. Absorbance  at 405 nm was 
measured using a microplate reader. All reactions were done at 37°C.  
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3. RESULTS AND DISCUSSION 
 
3.1.  Construction,expression and purification of Wgn-scFv gene 
The sequence of the VH and VL domain genes (DDBJ Accession No. LC192166), 
which were amplified by PCR using cDNA from the hybridoma cell line MAb 315A, 
showed that they encoded 116 and 108 amino acids, respectively (Fig. 18). After cloning 
the amplified genes into a plasmid, the VH and VL domains were assigned according to 
the Kabat and Chothia numbering plan (http://www.bioinf.org.uk/abs). These genes 
were subsequently assembled using SOE-PCR to construct a gene encoding a scFv with 
a flexible linker (GGGGS)n (n = 3, 5, or 7) and restriction enzyme sites at both ends 
(EcoRI and SalI) to generate three different Wgn–scFvs (3L, 5L, and 7L) constructs. 
Analysis of the nucleic acid sequences of the developed scFv genes on the plasmid 
vector revealed the presence of 717, 747 and 777bps encoding 239, 249 and 259 amino 
acids including the (GGGGS)  3, (GGGGS)  5 and (GGGGS)  7 linkers, for each 3L, 5L, 
and 7L, respectively.  
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Fig. 18: Nucleotide and deduced amino acid sequences of Wgn-scFv 
 
The assembled scFv genes were digested with the appropriate restriction 
enzymes and inserted into the pET28a (+) vector s to generate 3L, 5L, and 7L, 
respectively. For expression, a time-course expression experiment was performed to 
determine the optimum time required for expressing Wgn-scFv proteins. The data we 
obtained demonstrated that the expression level reached a peak  at 5 h after IPTG 
induction for all three proteins. I expressed three different scFv proteins with an N-
terminal hexahistidine tag. The proteins aggregated in the inclusion bodies were 
dissolved in 8 M urea and were purified using a metal chelator affinit y chromatography. 
Affinity purification yielded high quality scFv in large amounts (17.52 mg, 15.32 mg 
and 13.10 mg for every 1 L culture medium for 3L, 5L and 7L, respectively) (Fig. 18). 
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Fig. 19: SDS-PAGE analysis of anti-Wgn-scFvs 3L, 5L and 7L expressed in E.coli 
BL21 (DE3) 
Lane 1: Pre-IPTG induction; Lane 2: Post-IPTG induction; Lane 3: Soluble fraction;  
Lane 4: Inclusion body; Lane 5: Purified scFv. M: molecular weight markers.  
 
3.2.  Refolding of scFv against Wgn 
Protein refolding was required to regenerate antigen recognition. The scFvs which 
were purified from the inclusion bodies were inactive, and therefore the refolding 
strategy previously described by Umetsu et al. was used with a few modifications. As a 
result of  stepwise refolding of the purified Wgn-scFvs (3.0 mg), showed the yield of 
refolded Wgn-scFvs was to be 1.2 mg, 1.1 mg, and 1.1 mg for 3L, 5L, and 7L, 
respectively (Fig.19).  
The three recombinant Wgn-scFvs were used for an icELISA with Wgn-HSA as the 
coating antigen. POD-labeled anti-T7 tag conjugate was utilized as a secondary 
antibody. The IC50 of Wgn in the icELISA with 3L, 5L, and 7L are 6.21, 6.80, and 6.93 
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g /mL,  respectively.  Its sensitivity was no different than of the icELISA for Wgn with 
3L, 5L, and 7L. Fig. 20 shows a calibration curve for Wgn in the icELISA using 3L 
which is linear over the range of 1.56-50 g /mL.   
 
Fig. 20: Standard curve for Wgn based on the icELISA using Wgn-scFv 
 
3.3.  Development of icELISA using a scFv against Wgn 
The specificity of scFv was evaluated by the cross reactivities (CRs)  with other 
Wgn-related compounds. Their CRs were calculated by the computational expression 
from the previous report (Weiler et al., 1976).  Table 9 shows the CRs of the scFv 
towards Wgn and its related compounds. It also recognizes Wgn likewise anti -Wgn 
MAb 315A. In contrast to CRs of scFv against Wgn,determined to be 100%, the CRs 
towards wogonin, baicalein, baicalin, luteolin glucuronide, aipgenin glucuronide, 
daidzein, genistein, oroxylin A, oroxylin A glucuronide, and skullcapflavone II were 
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found to be less than 2.07%. The CR towards wogonin glucopyranoside was 37.8%, 
33.86%, and 33.62% for 3L, 5L, and 7L, respectively, because the glycoside linkage of 
Wgn is crucial for recognition by the anti -Wgn antibody. From the results of the yield, 
activity and selectivity of each scFv, it was concluded that 3L was the most suitable as 
the first antibody for the icELISA to analyze Wgn in S. Radix.  
 
Table 9: CRs of Wgn-scFv against Wgn and structurally related compounds  
 
 
Subsequently, the icELISA using 3L was validated for the quantitative determination of 
Wgn. The intra and inter assay precision of the icELISA was determined by testing six 
samples with varying concentrations of Wgn in assays performed together around the 
same time, and three sequential days, respectively. The results in Table 11 indicate that 
the most extreme RSD for the intra-assay was 4.28%, but was 9.96% for the inter assay 
RSD. The test results were affirmed that the icELISA using the 3L was sufficiently 
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reliable.  
Table 10: Inter and intra assay precision of the icELISA using Wgn-scFv  
 
 
3.4.  Analysis of S. Radixes with the icELISA using a scFv against Wgn 
After accepting our icELISA as a quantitative method, it was used to analyze various 
S. Radixes. The S. Radix samples were inspected by an icELISA utilizing the 
recombinant scFv, 3L. Table 11 shows that with regards to the quantitative data, the 
Wgn contents in S. Radix were determined to range from 20.21 to 23.52 μg/ mg dry 
weight. On the other hand, the data determined by the HPLC method was the Wgn 
contents in S. Radix to range from 17.13 to 21.43 μg / mg dry weight. The Wgn contents 
determined by the icELISA using 3L are similar to those by the HPLC method. As a 
result, the icELISA using 3L were reproducible and agreed with those of previous 
reports, supporting the practical utility of the icELISA using the recombinant anti-Wgn-
scFv, 3L as a method for the quantitative analysis of Wgn.  
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Table 11: Determination of Wgn in S. Radixes by the icELISA using anti -Wgn-scFv 
 
*: The root of S. baicalensis  cultivated in the herbal garden of Kyushu University.  
4. CONCLUSION 
All in all, the expression, purification and refolding of three kinds of scFv with 
linker regions of three different lengths, 3L, 5L, and 7L have been successfully 
performed. The recombinant scFv was applied to the icELISA for quantitative analysis 
of Wgn-related compounds. Among the prepared scFvs, 3L [VH-(GGGGS)3–VL] had 
advantages in yield, reactivity and sensitivity. The 3L was successfully utilized as the 
first antibody in icELISA for quantitative analysis of Wgn-related compounds, since 
the characteristics of 3L were similar to those of the MAb 315. The data suggests that 
the anti-Wgn scFv, 3L, could be used as an alternative to the MAb at a low cost; it is 
also applicable for immunoassays of Wgn in S. Radix. Also, the recombinant antibody 
technology can modify the property of the scFv against Wgn more sensitive and 
desirable as reported previously (Sakamoto et al., 2011).  
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CHAPTER 6 
 
An overview and comparison of two recombinant antigen-binding 
fragment and antigen-binding fragment from monoclonal antibody 
against wogonin glucuronide  
 
1. INTRODUCTION 
I prepared a monoclonal antibody (MAb 315A) showing specificity for Wgn, and we 
developed an icELISA using this novel MAb.  The immunoassay yield ed analysis 
results for multiple samples in a short period of time using simple and reliable protocols. 
However, the yield of the MAb 315A was insufficient due to the low production 
characteristics of the hybridoma. This hindered the facile application of the novel 
antibody to various immunochemical experiments.  
This report describes the preparation of a recombinant antibody derived from the 
MAb 315A to overcome the insufficient production of the MAb using a hybridoma 
culture.  
Antigen binding fragment (Fab) is made out of two antigen binding arms. Each 
formed in both the heavy and the light chain by one variable and one constant domain. 
In comparison, the size of Fab is somewhat greater than the scFv while it is one -6th of 
the full length IgG molecule. These days, the Fab turns into a mainstream design for 
therapeutic and analytical  methodologies. In light of its size and probability of genetic 
engineering, the achievement rate has been expanded.  
In this Chapter, I constructed and characterized Fab against Wgn, and assessed 
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their utility in an icELISA for the detection of Wgn (Fig. 21). 
 
Fig. 21: Structure of IgG antibody and Fab antibody 
 
2. MATERIALS AND METHODS 
 
2.1. Materials 
All materials and chemicals used in Chapter 4 and 5 were also used in Chapter 6. 
Anti-mouse IgG (Fab specific)-POD created in goat was obtained from Sigma-Aldrich 
(St. Louis, MO, USA). All other compounds and natural solvents were standard business 
results of analytical-reagent grade.   
 
2.2. Sample preparations 
Same samples which are used in  Chapter 4 and 5 were also used in Chapter 6.  
 
2.3. Synthesis of Wgn conjugates 
Same conjugates which are used in  Chapter 4 and 5 were also used in Chapter 6.  
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2.4. Strains, media, and vectors 
Same strains, media and vectors which are used in  Chapter 5 were also used in Chapter 
6. 
2.5.  Construction and expression of heavy and light chain encoding a Fab 
against Wgn 
Each and every one of the strains, media, and vectors which were used as a part 
of Chapter 5 were additionally used as a part of this Chapter. The VH-CH1 and VL-CL 
genes were amplified by PCR utilizing established antibody-specific primers (Krebber 
et al., 1997), and the PCR products were cloned into a pMD 20-T vector (Takara, Kyoto, 
Japan). After transformation of E. coli  JM109 cells with this ligation mixture, plasmid 
inserts were specifically screened from  E. coli colonies. The VH-CH1 and VL-CL 
specific primers for the construction of Wgn-Fab were listed in Table 12.  
 
Table 12: Primers used to construct the Wgn-Fab genes 
No. Name Sequences (5’ –  3’)  
1 VH-CH1-for-
EcoRI 
CGC GAA TTC CAG GTC CAG CTG CAG CAA CCT 
GGG 
2 VH-CH1-rev-SalI CGC GTC GAC CTA ACA ATC CCT GGG CAC AAT TTT 
3 VL-CL-for-EcoRI CGC GAA TTC GAC ATT GTG ATG ACC CAG TCT CTT 
4 VL-CL-rev-SalI TTT GTC GAC CTA ACA CTC ATT CCT GTT GAA GCT 
The restriction sites are underlined.  
 
The construction of each VH-CH1 and VL-CL gene, pET28/VH-CH1 and 
pET28/VL-CL, were performed using basically the same methodology used to set up 
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the Wgn-scFv. Expressed heavy and light chain were cultured in 1 L LB broth medium 
containing 50 µg/mL kanamycin. When the optical density of the culture at 660 nm 
achieved 0.6, IPTG was added to the culture reaching the final concentration of 0.5 mM. 
After incubating at 37°C for 12 h, the cells were collected by centrifugation, it re-
suspended in 50 mL of 20 mM of PB (pH 8.2) containing 0.5 M sodium chloride, and 
lysed by hen egg lysozyme (1 mg/mL). The lysate was set up by sonication, and then 
centrifuged at 9,000 rpm for 20 min to get dissolvable and insoluble fractions of heavy 
and light chain independently.  
The insoluble fractions of heavy and light chain were dissolved in 50 mL of 
buffer A (20 mM PB containing 8 M urea and 0.5 M NaCl) and applied to a column (1.0 
× 5.0 cm) containing His-bind resin (Novagen) equilibrated with buffer A. After sample 
application, non-particularly bound proteins were expelled with 100 mL of buffer A 
containing 20 mM imidazole. At that point, hexahistidine -tagged recombinant 
antibodies were eluted with 100 mL of buffer A containing 500 mM imidazole. The 
above purification protocol was performed for a second time; the purity of every 
recombinant protein was checked by SDS-PAGE analysis (Chapter 5). 
 
2.6.  Refolding of the heavy chain, light chain and Fab  
I was able to successfully obtain VH1-CH1 and VL-CL. To refold VH1-CH1 and 
VL-CL individually, I contrastingly refolded the VH1-CH1 and VL-CL with the same 
condition applied for the Wgn-cFv (Chapter 5). To refold Fab, a mixture of VH1-CH1 
and VL-CL solutions in buffer B (300 g/mL) to get Wgn-Fab was reduced with -ME 
and the solution which was applied to the stepwise dialysis portrayed as described in 
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Chapter 5. The solution is solubilized in buffer B (20 mM PB (pH 8.2), 200 mM NaCl, 
and 1 mM EDTA) containing 8 M urea, and refolded with some modification in the 
strategy reported by Umetsu et al. The Fab, VH1-CH1 and VL-CL was refolded by 
steady removal of urea by means of stepwise dialysis against buffer B containing urea 
(8, 4, 2, 1, 0.5, 0.25, 0.125, 0 M) and phosphate PBS. At the 2 – 0.125 M urea stages, 
400 mM L-arginine and 600 µM were reduced and oxidized glutathione were added to 
facilitate the formation of disulfide bonds. After stepwise dialysis, the refolded Fab 
solution was centrifuged at 9,000 rpm for 20 min at 4°C to expel aggregated proteins 
and was utilized for the ELISA examines as Wgn-Fab. The refolded Fab was examined 
by non-reducing SDS-PAGE. 
 
2.7.  Preparation and purification of Fab from MAb using immobilized papain   
The thermos logical pierce Fab preparation kit empowers productive Fab 
generation from IgG. This kit utilizes papain, a nonspecific thiol -endopeptidase, 
immobilized on agarose resin. Immobilized enzyme is favorable on the grounds that 
digestion can be instantly stopped by essentially expelling the IgG solution from the 
resin, bringing about a digest that is enzyme-free. Digestion by papain produces 50 kDa 
Fab and Fc fragments.  
 
3. RESULTS AND DISCUSSION 
 
3.1. Construction and expression of Wgn-Fab gene 
The cDNAs having VH1-CH1 and VL-CL fragment genes were amplified by 
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PCR using two sets of specific primers which contained appropriate restriction sites. 
The amplified genes were analyzed and amino acids of each gene were deduced.  
The sequence analyses of both genes showed 654 and 642 amino acids, 
respectively. In the wake of cloning the amplified genes, the VH1-CH1 and VL-CL 
domains were assigned by Kabat and Chothia numbering scheme 
(http://www.bioinf.org.uk/abs). The VH1-CH1 and VL-CL gene were subsequently 
inserted into the pET28a (+) vector to express recombinant proteins . From sequence 
analyses of two genes, VH1-CH1 and VL-CL genes were successfully obtained (Fig. 
22).   
 Fig. 22: Nucleotide and deduced amino acid sequence of VH-CH1 and VL-CL 
  
3.2. Purification and refolding of Fab against Wgn 
The E. coli BL21 (DE3) was transformed utilizing the construct VH1-
CH1/pET28a (+) and VL-CL v/pET28a (+), and the VH-CH1 and VL-CL was expressed 
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by addition of IPTG induction. SDS analysis of recombinant proteins in E. coli  
exhibited that the VH-CH1 and VL-CL were expressed in the insoluble fraction. They 
were purified using the same methodology as Wgn-scFv from an inclusion body and 
were acquired in high yields, 15.77 mg and 10.92 mg for each VH-CH1 and VL-CL 
from 1 L of culture, respectively. A molecular weight of 27 kDa was determined to be 
12.5% SDS-PAGE in Fig. 23, which was very close to the theoretical values (27,305 Da 
and 27,979 Da for VH1-CH1 and VL-CL respectively) predicted for each fragment with 
the tags. 
 
Fig. 23: SDS-PAGE analysis of VH-CH1 and VL-CL expressed in E.coli BL21 (DE3) 
M: marker; Lane 1: Before IPTG induction; Lane 2: After IPTG induction; Lane 3: 
Soluble fraction; Lane 4: Inclusion body; Purified（ Lane 5 VH –CH1; Lane 6 VL –
CL） 
 
 Purified recombinant VH-CH1 and VL-CL were in inactive forms, they needed 
to be refolded to generate antigen recognition. I refolded and otained active VH1-CH1 
and VL-CL where I have also obtained recombinant Fab. To compare active recombinant 
Fab with individual VH-CH1 and VL-CL, I followed the same processes for three 
refoldings. Fig. 24 shows the results; VH-CH1 and VL-CL were very close to the 
theoretical values where they are not connected with each other with sulfide bond to be 
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in 50 kDa. But the same the active recombinant Fab show ed the band on near 25 and 50 
kDa. According to the data, i t means recombinant Fab shows the validated data, because 
there is no relation with the 25 kDa which was seen in SDS -PAGE.  
 
Fig. 24: Native SDS page M: marker; 1: Refolded VL-CL; 2: Refolded VH-CH1; 3: 
Refolded Fab 
3.3.  Development of the icELISA using a Fab against Wgn 
Then, I prepared Fab from MAb (mFab) by using the Thermos pierce tm Fab 
preparation kit.  It was prepared to compare the refolded Fab (rFab). The rFab and mFab 
were compared in terms of analytical techniques for Wgn related compounds. The rFab 
and mFab were utilized as a part of an icELISA utilizing Wgn-HSA as a coating antigen. 
Fig. 25 demonstrates that standard curves for Fab antibodies were generated and were 
linear from 1.56 μg/mL to 50 μg/mL for Wgn.  
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Fig. 25: Standard curves of Wgn using Wgn-Fab (refolded) in the icELISA. 
 
The specificity of Fab (two different Fabs i.e. rFab and mFab) was determined by their 
CRs with other Wgn related compounds utilizing the icELISA. It was calculated by 
using the equation created by Weiler and Zenk. Table 14 shows CRs of the Fab against 
Wgn and its related compounds, it recognizes Wgn, as well as different flavonoids. As 
compared with CRs for Wgn (CR: 100%), CRs for wogonin, baicalein, baicalin, luteolin 
glucuronide, aipgenin glucuronide, daidzein, genistein, oroxylin A, oroxylin A 
glucuronide and skullcapflavone II were less than 2.07. However, the CR for wogonin 
glucopyranoside, rFab and mFab were 39.01 %, 40.67 % and 40.67% respectively. This 
was of the vitality of the glycoside linkage of wogonin glycoside for acknowledgment 
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of the counter acting agent.  There was no distinction between two different Fabs in CRs. 
 
Table 13: CRs of Fabs against Wgn and structurally related compounds  
 
 
To affirm the icELISA utilizing the Fab,  the intra and inter assay precision was 
assessed for the icELISA by testing nine samples of various Wgn concentration in nine 
assays performed together around the same time and on three continuous days  
respectively. The Table 14 demonstrates that the most extreme RSD of intra assay was 
4.32%, while the inter assay was 9.76%. The assay results were confirmed using the 
Fab, revealing that the developed icELISA was sufficiently accurate and reliable for 
quantitative analysis of Wgn.  
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Table 14: Inter and intra assay precision of the icELISA for anti-Wgn Fab 
 
 
3.4.  Analysis of S. Radixes with the icELISA using a Fab against Wgn 
After validating the icELISA as a quantitative method, the method was utilized for 
the analysis of S. Radixes, a main source of Wgn. The experimental results were highly 
reproducible and concurred with previous reports, supporting the pragmatic utility of 
the icELISA utilizing the recombinant Fab against Wgn as a strategy for quantitatively 
analyzing Wgn. With regards to the quantitative data, the contents of Wgn in S. Radixes 
were determined to be from 17.77 to 20.64 μg/mg dry wt. On the other hand, the data 
by the icELISA were general higher than those by HPLC where the contents of Wgn in 
S. Radixes were determined to be from 17.13 to 21.43μg/mg dry wt.  
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Table 15: Determination of Wgn in S. Radixes by the icELISA using anti-Wgn Fab 
 
*: The root of S. baicalensis  cultivated in the herbal garden of Kyushu University.  
 
4. CONCLUSION 
Taking everything into account, great development, expression, purification and 
refolding of VH-CH1 and VL-CL, and functional recombinant Fab and arranged Fab 
from MAb were accomplished. It was applied to icELISA thus, there is no distinction 
between rFab and mFAb. VH-CH1 and VL-CL were expressed, purified and refolded 
contrastingly and refolded together with VH-CH1 and VL-CL to get recombinant Fab 
containing sulfide bond, between two domains, against Wgn-Fab, there is no connection 
with VH-CH1 and VL-CL n in the time of refolding. Despite the fact that the 
purification of recombinant Fab can't done yet it doesn't impact in ELISA. Although 
the specificity of MAb 315A, Wgn-scFv3, Wgn-scFv5, and Wgn-scFv7, anti-Wgn Fab 
and MFab were not so different, the developed icELISA using all antibodies 
demonstrated enough affectability and exactness.  
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CHAPTER 7 
 
CONCLUSIONS 
 
  In Chapters 2 and 4, I successfully prepared MAbs against Sal A and Wgn and 
characterized the MAbs to show novel recognition to each compound. Subsequently, the 
MAbs were applied to icELISA for the determination of Sal A and Wgn. The icELISA 
was evaluated to be a simultaneous analytical method which is useful for a screening 
system of each species having high content of Sal A or Wgn.  
The pharmacological researches regarding Sal A and Wgn have been conducted and 
reported. Sal A showed various pharmacological and neuro biochemical activities where 
Wgn has been used for antifebrile and detoxification purposes . This suggests that Sal A 
and Wgn are widely-recognized as a potential drug candidate. Immunoassays using 
MAb 3D5 also has potential uses as analysis tool  to contribute in aforementioned 
research fields.  In addition, as S. Radix is one of the important crude drugs in Kampo 
Medicines, the icELISAcan be a potential as a quality control method of the crude drug 
and a breeding study of S. Radix  containing Wgn in high concentration.  
In Chapter 3, ICA using MAb 3D5 was successfully developed and applied to 
combined technique consist ing of ICA and icELISA for the determination of salvinorins , 
which contained only in S. divinorum . The icELISA and ICA were validated by analysis 
of various plant materials and the results demonstrated their usability as a 
differentiation method for S. divinorum. This is a first report regarding the 
establishment of an immunochemical method to analyze salvinorins and discern S. 
 70 
 
divinorum using a combination of immunoassays . S. divinorum is known as an abused 
drug in many countries and it is necessary to prevent the abuse of this plant. The 
combined immunochemical system must be ideal to find products of S. divinorum in the 
market promptly and the spread of this plant can be precluded consequently.  
In Chapters 5 and 6, the preparation of recombinant antibodies against Wgn was 
performed. Consequently, the abundant expression system of recombinant antibody 
scFv against Wgn with different linker length were developed, and applied to the 
icELISA. The scFv with (GGGGS)  3 showed the most satisfied characteristics among 
three kinds of the scFvs against Wgn. The icELISA using scFv with (GGGGS)  3 was 
validated as a quantitative analytical method in terms of its utility and reliability by 
testing the inter and intra assay variations for Wgn determination. (Chapter 5) 
Concerning the Fab against Wgn, it also showed activity and recognition ability to Wgn. 
Subsequently, the icELISA using the recombinant Fab  was developed and was validated 
as a quantitative analytical method by testing the multilateral evaluations for Wgn 
determination from S. Radix in terms of its utility and reliability. The immunoassay 
using the recombinant Fab was a quantitative method that is useful as well as the 
icELISA using the scFv.  
In conclusion, the immunoassays for Sal A and Wgn developed in this research are 
sensitive, reliable and convenient for qualitative and quantitative analyses for Sal A 
and Wgn, respectively. These methods have promising applications in studies involving 
breeding of valuable medicinal plants and efficient evaluation of crude drugs and plant 
products. 
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